ACADIA Pharmaceuticals Company Profile (NASDAQ:ACAD)

About ACADIA Pharmaceuticals (NASDAQ:ACAD)

ACADIA Pharmaceuticals logoACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer's disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ACAD
  • CUSIP: N/A
  • Web:
  • Market Cap: $4.39 billion
  • Outstanding Shares: 122,400,000
Average Prices:
  • 50 Day Moving Avg: $36.94
  • 200 Day Moving Avg: $31.74
  • 52 Week Range: $20.68 - $41.20
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -18.28
  • P/E Growth: -0.42
Sales & Book Value:
  • Annual Revenue: $62.99 million
  • Price / Sales: 69.62
  • Book Value: $3.39 per share
  • Price / Book: 10.57
  • EBITDA: ($305,320,000.00)
  • Net Margins: -485.14%
  • Return on Equity: -62.08%
  • Return on Assets: -57.18%
  • Current Ratio: 10.85%
  • Quick Ratio: 10.70%
  • Average Volume: 1.42 million shs.
  • Beta: 3.8
  • Short Ratio: 13.54

Frequently Asked Questions for ACADIA Pharmaceuticals (NASDAQ:ACAD)

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.72) by $0.17. The firm had revenue of $30.50 million for the quarter, compared to analyst estimates of $20.02 million. ACADIA Pharmaceuticals had a negative net margin of 485.14% and a negative return on equity of 62.08%. The business's revenue for the quarter was up 30400.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.63) EPS. View ACADIA Pharmaceuticals' Earnings History.

When will ACADIA Pharmaceuticals make its next earnings announcement?

ACADIA Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for ACADIA Pharmaceuticals.

Where is ACADIA Pharmaceuticals' stock going? Where will ACADIA Pharmaceuticals' stock price be in 2017?

13 equities research analysts have issued twelve-month price objectives for ACADIA Pharmaceuticals' shares. Their forecasts range from $25.00 to $61.00. On average, they expect ACADIA Pharmaceuticals' stock price to reach $47.54 in the next year. View Analyst Ratings for ACADIA Pharmaceuticals.

What are analysts saying about ACADIA Pharmaceuticals stock?

Here are some recent quotes from research analysts about ACADIA Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia. " (10/16/2017)
  • 2. HC Wainwright analysts commented, "HARMONY Study Initiation: Killing Multiple" Birds With One Stone? Reit Buy and $60 PT Initiation of the Ph3 HARMONY study is one step forward with our bull thesis. With the initiation of HARMONY study in dementia-related psychosis (DRP) and discontinuation of SEREN study in AD agitation, we applaud what we view as a smart move by Acadia of pursuing a broader indication for pimavanserin, and more importantly, doing so with a solid clinical plan moving forward. At first glance, the seemingly bold move into DRP from ADP may appear over-ambitious (killing multiple" birds with one stone). However, we note that a psychosis focus/approach may prove to be a smart play from both the commercial point of view and also from the mechanistic perspective. The blessing from the FDA with a Breakthrough Designation further elevates our sanguine outlook for the program. We highlight the significant upside coming with the DRP expansion as the target market is potentially bigger than ADP alone (if we assume ADP comprises 70% of the DRP)." (10/5/2017)
  • 3. Needham & Company LLC analysts commented, "Acadia reported $11.9M in 4Q16 Nuplazid sales, above our $9.0M estimate. Mgmt noted steady growth in number of prescribers, repeat prescribers, and new patients. Company also announced plan to expand sales force by 20 reps to address long-term care opportunity. There are no immediate plans to provide 2017 sales guidance. We believe stock is attractive given Nuplazid launch trajectory and likelihood for label expansion in long-term. Stock likely to be driven by sales in 2017 and Phase 2/3 results in other indications in 2018/ 2019. Acadia may be an attractive M&A target. BUY." (3/1/2017)

Are investors shorting ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals saw a decline in short interest in the month of September. As of September 29th, there was short interest totalling 6,510,387 shares, a decline of 60.7% from the September 15th total of 16,574,500 shares. Based on an average trading volume of 1,050,533 shares, the short-interest ratio is presently 6.2 days. Currently, 5.3% of the shares of the company are short sold.

Who are some of ACADIA Pharmaceuticals' key competitors?

Who are ACADIA Pharmaceuticals' key executives?

ACADIA Pharmaceuticals' management team includes the folowing people:

  • Stephen R. Biggar M.D. Ph.D., Chairman of the Board
  • Stephen R. Davis, President, Chief Executive Officer, Director
  • Todd S. Young, Executive Vice President, Chief Financial Officer
  • Glenn F. Baity, Executive Vice President, General Counsel, Secretary
  • Srdjan Stankovic M.D., Executive Vice President, Head - Research and Development
  • Michael J. Yang, Executive Vice President, Chief Commercial Officer
  • Edmund P. Harrigan M.D., Director
  • Julian C. Baker, Independent Director
  • Laura A. Brege, Independent Director
  • James M. Daly, Independent Director

Who owns ACADIA Pharmaceuticals stock?

ACADIA Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BAKER BROS. ADVISORS LP (22.10%). Company insiders that own ACADIA Pharmaceuticals stock include Bros Advisors Lp Baker, Edmund Harrigan, Glenn Baity, Leslie L Iversen, LP 14159 and Terrence O Moore. View Institutional Ownership Trends for ACADIA Pharmaceuticals.

How do I buy ACADIA Pharmaceuticals stock?

Shares of ACADIA Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ACADIA Pharmaceuticals' stock price today?

One share of ACADIA Pharmaceuticals stock can currently be purchased for approximately $35.83.

MarketBeat Community Rating for ACADIA Pharmaceuticals (NASDAQ ACAD)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  457 (Vote Outperform)
Underperform Votes:  193 (Vote Underperform)
Total Votes:  650
MarketBeat's community ratings are surveys of what our community members think about ACADIA Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.77)
Consensus Price Target: $47.54 (32.68% upside)
Consensus Price Target History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Price Target History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Analysts' Ratings History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/12/2017Jefferies Group LLCReiterated RatingBuy$47.00N/AView Rating Details
10/9/2017Leerink SwannReiterated RatingMarket PerformN/AView Rating Details
10/6/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$45.00N/AView Rating Details
10/5/2017J P Morgan Chase & CoSet Price TargetBuy$50.00N/AView Rating Details
10/5/2017Piper Jaffray CompaniesReiterated RatingBuy$54.00 -> $61.00N/AView Rating Details
10/5/2017Bank of America CorporationBoost Price TargetBuy -> Positive$40.00 -> $46.00N/AView Rating Details
10/5/2017JMP SecuritiesBoost Price TargetOutperform$47.00 -> $50.00N/AView Rating Details
10/5/2017HC WainwrightReiterated RatingBuy$60.00N/AView Rating Details
10/2/2017Ladenburg Thalmann Financial ServicesReiterated RatingBuy$48.00 -> $50.00LowView Rating Details
9/17/2017Needham & Company LLCReiterated RatingBuy$49.00LowView Rating Details
8/10/2017Cowen and CompanyReiterated RatingOutperform$42.00 -> $46.00HighView Rating Details
5/22/2017Rodman & RenshawReiterated RatingBuy$60.00LowView Rating Details
10/19/2016Roth CapitalReiterated RatingNeutral$25.00N/AView Rating Details
8/5/2016AegisDowngradeBuy -> Hold$54.00 -> $41.00N/AView Rating Details
(Data available from 10/19/2015 forward)


Earnings History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Earnings by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Earnings History by Quarter for ACADIA Pharmaceuticals (NASDAQ ACAD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.63)N/AView Earnings Details
8/8/2017Q2 2017($0.72)($0.55)$20.02 million$30.50 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.73)($0.72)$15.17 million$15.30 millionViewListenView Earnings Details
2/28/2017Q416($0.65)($0.65)$9.05 million$12.00 millionViewListenView Earnings Details
11/7/2016Q316($0.56)($0.61)$2.90 million$5.30 millionViewListenView Earnings Details
8/4/2016Q216($0.49)($0.63)$0.71 million$0.97 millionViewListenView Earnings Details
5/5/2016Q116($0.42)($0.45)$0.22 millionViewListenView Earnings Details
2/29/2016Q415($0.38)($0.45)$0.02 millionViewListenView Earnings Details
11/5/2015Q315($0.40)($0.39)$0.05 million$0.04 millionViewListenView Earnings Details
8/6/2015Q215($0.33)($0.39)$0.06 millionViewListenView Earnings Details
5/7/2015Q115($0.25)($0.40)$0.09 millionViewListenView Earnings Details
2/26/2015Q414($0.26)($0.28)$0.08 million$0.05 millionViewListenView Earnings Details
11/10/2014Q3($0.12)($0.25)$0.02 millionViewListenView Earnings Details
8/5/2014Q2($0.17)($0.22)$0.10 million$0.03 millionViewListenView Earnings Details
5/6/2014Q1($0.13)($0.19)$0.50 million$0.03 millionViewListenView Earnings Details
2/27/2014Q4($0.14)($0.13)ViewListenView Earnings Details
8/6/2013Q2 2013($0.09)($0.11)$0.45 million$451.00 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.08)($0.08)$0.45 million$0.42 millionViewListenView Earnings Details
11/5/2012Q312($0.09)($0.04)$1.90 million$3.50 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for ACADIA Pharmaceuticals (NASDAQ:ACAD)
2017 EPS Consensus Estimate: ($2.28)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.75)($0.53)($0.64)
Q2 20172($0.71)($0.48)($0.60)
Q3 20172($0.64)($0.44)($0.54)
Q4 20172($0.62)($0.39)($0.51)
(Data provided by Zacks Investment Research)


Dividend History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Insider Ownership Percentage: 22.25%
Institutional Ownership Percentage: 97.10%
Insider Trades by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Institutional Ownership by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Insider Trades by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/5/2017Glenn BaityEVPSell37,500$40.91$1,534,125.00View SEC Filing  
8/30/2017Glenn BaityEVPSell26,507$34.87$924,299.09View SEC Filing  
8/9/2017Glenn BaityEVPSell14,322$34.88$499,551.36View SEC Filing  
7/20/2017Glenn BaityEVPSell38,097$30.00$1,142,910.00View SEC Filing  
6/22/2017Glenn BaityEVPSell1,903$30.00$57,090.00View SEC Filing  
2/16/2017Terrence O. MooreEVPSell157,540$39.77$6,265,365.80View SEC Filing  
12/27/2016Glenn BaityEVPSell9,800$30.46$298,508.00View SEC Filing  
12/20/2016Glenn BaityEVPSell10,000$30.00$300,000.00View SEC Filing  
8/16/2016Edmund HarriganDirectorBuy1,000$32.97$32,970.00View SEC Filing  
8/10/2016Bros. Advisors Lp BakerDirectorBuy1,303,030$33.00$42,999,990.00View SEC Filing  
7/12/2016Glenn BaityEVPSell16,000$35.00$560,000.00View SEC Filing  
7/11/2016Glenn BaityEVPSell4,057$35.00$141,995.00View SEC Filing  
4/18/2016Leslie L IversenDirectorSell33,697$33.53$1,129,860.41View SEC Filing  
4/1/2016Bros. Advisors Lp BakerDirectorBuy1,449,090$27.08$39,241,357.20View SEC Filing  
1/7/2016L.P. 14159DirectorBuy2,586,206$29.00$74,999,974.00View SEC Filing  
11/11/2015Leslie L. IversenDirectorSell30,000$36.01$1,080,300.00View SEC Filing  
1/15/2015Michael T BorerDirectorSell27,973$33.02$923,668.46View SEC Filing  
1/14/2015Uli HacksellCEOSell30,000$33.98$1,019,400.00View SEC Filing  
12/15/2014Mary Ann GrayDirectorSell12,250$31.74$388,815.00View SEC Filing  
12/15/2014Uli HacksellCEOSell30,000$31.00$930,000.00View SEC Filing  
11/26/2014Michael T BorerDirectorSell15,000$30.05$450,750.00View SEC Filing  
11/26/2014Roger MillsCMOSell25,000$30.09$752,250.00View SEC Filing  
11/24/2014Uli HacksellCEOSell30,000$29.28$878,400.00View SEC Filing  
11/21/2014William Mcdowall WellsDirectorSell5,810$29.00$168,490.00View SEC Filing  
10/8/2014Uli HacksellCEOSell30,000$24.15$724,500.00View SEC Filing  
9/15/2014Laura BregeDirectorSell10,000$28.07$280,700.00View SEC Filing  
9/12/2014William Mcdowall WellsDirectorSell9,190$29.15$267,888.50View SEC Filing  
9/10/2014Uli HacksellCEOSell30,000$27.36$820,800.00View SEC Filing  
8/15/2014Uli HacksellCEOSell15,000$22.89$343,350.00View SEC Filing  
7/14/2014Uli HacksellCEOSell20,000$22.22$444,400.00View SEC Filing  
6/16/2014Uli HacksellCEOSell20,000$23.10$462,000.00View SEC Filing  
6/9/2014William Mcdowall WellsDirectorSell15,000$23.03$345,450.00View SEC Filing  
5/1/2014Torsten RasmussenDirectorSell32,857$20.03$658,125.71View SEC Filing  
4/15/2014Uli HacksellCEOSell25,000$17.75$443,750.00View SEC Filing  
4/4/2014Thomas AasenCFOSell15,000$22.48$337,200.00View SEC Filing  
4/4/2014Torsten RasmussenDirectorSell30,000$21.98$659,400.00View SEC Filing  
3/5/2014Bros. Advisors Lp BakerDirectorBuy526,316$28.50$15,000,006.00View SEC Filing  
2/26/2014Glenn BaityVPSell42,000$30.28$1,271,760.00View SEC Filing  
11/1/2013Torsten RasmussenDirectorSell37,692$23.00$866,916.00View SEC Filing  
11/1/2013Uli HacksellCEOSell15,000$23.24$348,600.00View SEC Filing  
10/10/2013Laura BregeDirectorSell10,000$21.63$216,300.00View SEC Filing  
10/1/2013Thomas H AasenCFOSell30,000$27.87$836,100.00View SEC Filing  
9/20/2013Roger MillsCMOSell35,965$25.01$899,484.65View SEC Filing  
9/12/2013Lester Ph KaplanDirectorSell66,356$22.90$1,519,552.40View SEC Filing  
9/10/2013Laura BregeDirectorSell46,153$22.80$1,052,288.40View SEC Filing  
9/3/2013Torsten RasmussenDirectorSell40,000$20.28$811,200.00View SEC Filing  
8/26/2013Mary Ann GrayDirectorSell15,000$20.68$310,200.00View SEC Filing  
8/13/2013Thomas AasenCFOSell60,000$20.15$1,209,000.00View SEC Filing  
8/13/2013Uli HacksellCEOSell52,771$20.14$1,062,807.94View SEC Filing  
6/5/2013Felix BakerDirectorBuy2,340,314$14.34$33,560,102.76View SEC Filing  
5/15/2013Felix BakerDirectorBuy1,993,000$12.50$24,912,500.00View SEC Filing  
4/12/2013Glenn BaityVPSell60,000$12.42$745,200.00View SEC Filing  
4/11/2013Thomas H AasenCFOSell40,000$11.06$442,400.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Latest Headlines for ACADIA Pharmaceuticals (NASDAQ:ACAD)
DateHeadline logoACADIA Pharmaceuticals Inc. (ACAD) Receives Average Rating of "Buy" from Analysts - October 19 at 2:36 PM logoInstitutional Investors Ramp Up Stakes In ACADIA Pharmaceuticals After FDA Milestone - (blog) - October 18 at 3:41 PM logoACADIA Pharmaceuticals Inc. (ACAD) Cut to "Hold" at Zacks Investment Research - October 16 at 9:24 PM logoAcadia: A Long-Term Investment - Seeking Alpha - October 16 at 3:32 PM logoACADIA Pharmaceuticals Inc. (ACAD) Stock Rating Reaffirmed by Jefferies Group LLC - October 15 at 6:32 PM logoLilly's Verzenio Gets Priority Review in First-Line Setting - October 13 at 3:19 PM logoACADIA Pharmaceuticals Inc. (ACAD) Sees Large Drop in Short Interest - October 13 at 1:32 AM logoHere's Why Intercept (ICPT) Stock Lost 37% So Far in 2017 - October 12 at 8:37 PM logoShort Interest Plummets 60.7% For ACAD - October 11 at 3:35 PM logoETFs with exposure to ACADIA Pharmaceuticals, Inc. : October 11, 2017 - October 11 at 3:35 PM logoWhy Should You Invest in Novo Nordisk (NVO) Stock Right Now - October 10 at 3:29 PM logoEmergent BioSolutions Acquires Sanofi's Smallpox Vaccine Unit - October 9 at 3:36 PM logoLeerink Swann Reaffirms "Market Perform" Rating for ACADIA Pharmaceuticals Inc. (ACAD) - October 9 at 2:34 PM logoJ P Morgan Chase & Co Analysts Give ACADIA Pharmaceuticals Inc. (ACAD) a $50.00 Price Target - October 7 at 4:56 PM logoACADIA Pharmaceuticals Inc. (ACAD) Expected to Post Quarterly Sales of $31.52 Million - October 7 at 11:02 AM logoACADIA Pharmaceuticals Inc. (ACAD) Receives "Neutral" Rating from Goldman Sachs Group, Inc. (The) - October 6 at 9:08 PM logoACADIA Pharmaceuticals Inc. (ACAD) EVP Glenn Baity Sells 37,500 Shares - October 6 at 7:24 PM logoPros And Cons Of All The News Out Of Acadia Pharma This Week - Benzinga - October 6 at 3:44 PM logoSelling The News In Acadia Pharmaceuticals - Benzinga - October 6 at 3:44 PM logoPros And Cons Of All The News Out Of Acadia Pharma This Week - October 6 at 9:42 AM logoACADIA Pharmaceuticals Initiates Phase III Study of Pimavanserin in Dementia-Related Psychosis - Business Wire (press release) - October 5 at 8:12 PM logoACADIA Pharmaceuticals Inc. (ACAD) PT Raised to $50.00 - October 5 at 7:34 PM logoACADIA Pharmaceuticals Inc. (ACAD) Earns Buy Rating from Piper Jaffray Companies - October 5 at 3:39 PM logoAcadia's FDA Breakthrough Designation For Pimavanserin Draws Mixed Response - October 5 at 2:47 PM logoACADIA Pharmaceuticals Inc. (ACAD) Is Up On FDA Breakthrough Designation - October 5 at 12:34 PM logoGet a report before you buy ACADIA Pharmaceuticals, Deckers Outdoor Corp, GoPro, Shopify Inc. or United Parcel Service stock. - October 5 at 12:34 PM logoACADIA's Antipsychotic Drug Gets Breakthrough Therapy Status - October 5 at 12:34 PM logoACADIA Pharmaceuticals Initiates Phase III Study of Pimavanserin in Dementia-Related Psychosis - October 5 at 12:34 PM logo2 Stocks Move in After-Hours Trading - October 5 at 12:34 PM logoAcadia shares rise on FDA dementia drug designation - October 5 at 12:34 PM logoAcadia Pharma Stock Rockets On Drug Breakthrough Nod - October 5 at 12:34 PM logoAcadia Pharma Could Rise Another 25 Percent to $50 - October 5 at 12:34 PM logoACADIA's Antipsychotic Drug Gets Breakthrough Therapy Status - October 5 at 12:34 PM logoThis Biotech Rockets — Then Dips — After FDA Breakthrough Win - October 5 at 12:34 PM logoACADIA Pharmaceuticals Inc. (ACAD) PT Raised to $46.00 - October 5 at 11:48 AM logoACADIA Pharmaceuticals Inc. (ACAD) Given Buy Rating at HC Wainwright - October 5 at 10:08 AM logoAnalyzing ACADIA Pharmaceuticals (ACAD) & The Competition - October 3 at 10:56 AM logoAllergan Authorizes New $2B Share Buyback Plan, Stock Up - October 2 at 3:09 PM logoACADIA Pharmaceuticals' (ACAD) Buy Rating Reaffirmed at Ladenburg Thalmann Financial Services - October 2 at 1:56 PM logoBiotech Acadia Could Rise 30 Percent To $50 - September 28 at 1:45 AM logoACADIA Pharma (ACAD) Presents At Ladenburg Thalmann 2017 Healthcare Conference - Slideshow - September 28 at 1:45 AM logoACADIA Pharmaceuticals Inc. (ACAD) Given Average Rating of "Buy" by Analysts - September 24 at 2:48 PM logoCommit To Buy Acadia Pharmaceuticals At $25, Earn 8.2% Using Options - September 23 at 9:37 AM logoHead-To-Head Contrast: INC Research Holdings (INCR) & ACADIA Pharmaceuticals (ACAD) - September 21 at 12:44 AM logoTechnical Reports on Biotech Equities -- Vanda Pharma, ACADIA Pharma, Achillion Pharma, and Agios Pharma - PR Newswire (press release) - September 20 at 3:17 PM logoAcadia: Where's The Upside From Current Levels? - Seeking Alpha - September 20 at 3:17 PM logoSupernus Drops SPN-810's Lower Dose Test in Phase III Trials - September 19 at 8:24 PM logoSupernus Drops SPN-810's Lower Dose Test in Phase III Trials - September 19 at 8:23 PM logoACADIA Pharmaceuticals to Present at the Ladenburg Thalmann ... - Business Wire (press release) - September 19 at 3:23 PM logoACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26, 2017 - September 19 at 3:23 PM



ACADIA Pharmaceuticals (ACAD) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.